Argenica Therapeutics Limited (ASX:AGN) Share Price Falls 5.56% as Stock Trades Within Daily Range

Anjali Anand

13 August 2026 09:40 PM AEST

Argenica Therapeutics Limited (ASX:AGN) Share Price Falls 5.56% as Stock Trades Within Daily Range

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Argenica Therapeutics Limited (ASX:AGN) shares closed lower at $0.170 after declining 5.555% during the session.
The stock traded within a daily range of $0.170 to $0.180.
Trading Volume reached 28,907 shares during the session.
Market capitalisation stood at $23.12M based on the latest provided figures.
The share price remained within its 52-week range of $0.087 to $0.770.

Overview

Argenica Therapeutics Limited (ASX:AGN) is listed on the Australian Securities Exchange and operates within the healthcare sector. The company is classified under the Pharmaceuticals, Biotechnology & Life Sciences industry group. This article provides an educational summary of the company’s latest available share price activity and market statistics based on the provided data.

The article covers available trading information, including share price movement, trading volume, market capitalisation, share structure and historical price range. It is intended to provide a factual overview of market activity and does not represent financial advice or a recommendation regarding the company’s shares.

Share Price Movement

Shares of Argenica Therapeutics Limited (ASX:AGN) closed at $0.170, representing a decline of $0.009 or 5.555% compared with the previous close of $0.180. During the trading session, the stock moved between an intraday high of $0.180 and an intraday low of $0.170.

The difference between the day’s highest and lowest prices reflects the trading range observed during the session. The stock traded within a range of $0.010 between the session high and low, showing the price movement recorded during the trading period.

The 52-week trading range for Argenica Therapeutics Limited was recorded between $0.087 and $0.770. This range provides historical context regarding the highest and lowest prices reached by the stock over the previous 12-month period.

Trading Volume and Market Capitalisation

Argenica Therapeutics Limited recorded trading volume of 28,907 shares during the session. Trading volume represents the number of shares exchanged between buyers and sellers and is commonly reviewed alongside share price movements to understand the level of market participation.

The average volume for Argenica Therapeutics Limited was recorded at 276,502 shares. Comparing the latest trading volume with the stated average volume provides a reference point for the level of activity observed during the session.

The company’s Market Capitalisation was recorded at $23.12M based on the latest provided market data. Market capitalisation represents the total Market Value of a company’s Issued Shares and is calculated using the share price and shares on issue.

Share Information and Trading Details

Argenica Therapeutics Limited has 128,456,712 shares on issue, with its share structure classified as ordinary fully paid shares. The company was listed on the Australian Securities Exchange on 11 June 2021.

The bid and offer range was recorded between $0.170 and $0.175, representing the available quoted buying and selling levels during the trading session.

The stock’s daily trading range of $0.170 to $0.180 highlights the movement recorded throughout the session. Such market statistics provide a snapshot of trading activity at a particular point in time.

Healthcare Sector Context

Argenica Therapeutics Limited is categorised within the healthcare sector, specifically under the Pharmaceuticals, Biotechnology & Life Sciences industry group. Companies within this category generally operate across pharmaceutical development, biotechnology activities and related life sciences areas.

Individual share price movements can be influenced by factors including company-specific developments, trading activity and broader market conditions. A single Trading session reflects short-term market activity and does not represent the complete performance history of a listed company.

Conclusion

In summary, Argenica Therapeutics Limited (ASX:AGN) shares closed at $0.170 after recording a decline of 5.555% during the latest reported session. The stock traded between $0.170 and $0.180, with trading volume of 28,907 shares and a market capitalisation of $23.12M. The available market statistics, including the 52-week range, shares on issue and trading activity, provide an educational overview of the company’s latest market position based on the supplied information.

Frequently Asked Questions (FAQs)

FAQs

Q: What was the closing share price of Argenica Therapeutics Limited (ASX:AGN)?

A:Argenica Therapeutics Limited (ASX:AGN) closed at $0.170 based on the latest provided market data.

Q: How much did AGN shares decline during the session?

A:The share price declined by $0.009, representing a decrease of 5.555% from the previous close of $0.180.

Q: What was the trading volume for Argenica Therapeutics Limited?

A:The trading volume for the session was 28,907 shares.

Q: What is the market capitalisation of Argenica Therapeutics Limited?

A:The company’s market capitalisation was recorded at $23.12M based on the provided figures.

Q: What was the 52-week trading range for ASX:AGN?

A:The 52-week trading range for Argenica Therapeutics Limited was between $0.087 and $0.770.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.